Department of Pharmacy, Hebei University of Science and Technology, Shijiazhuang, PR China.
Nanomedicine. 2013 Feb;9(2):174-84. doi: 10.1016/j.nano.2012.06.003. Epub 2012 Jul 5.
The targeted delivery of anticancer agents is a promising field in anticancer therapy. Mesenchymal stem cells (MSCs) have inherent tumor-tropic and migratory properties, which allow them to serve as vehicles for targeted drug delivery systems for isolated tumors and metastatic diseases. MSCs have been successfully studied and discussed as a vehicle for cancer gene therapy. However, MSCs have not yet been discussed adequately as a potential vehicle for traditional anticancer drugs. In this review, we will examine the potential of MSCs as a targeted-delivery vehicle for anticancer drug-loaded nanoparticles (NPs), summarize various challenges, and discuss possible solutions for these challenges.
In this review, the feasibility of mesenchymal stem cell-based targeted delivery of anticancer agents is discussed.
在癌症治疗中，靶向抗癌药物输送是一个很有前景的领域。间充质干细胞（MSCs）具有固有的肿瘤趋向性和迁移特性，这使它们能够作为针对孤立肿瘤和转移性疾病的靶向药物输送系统的载体。MSCs 已被成功地作为癌症基因治疗的载体进行了研究和讨论。然而，MSCs 作为传统抗癌药物的潜在载体尚未得到充分讨论。在这篇综述中，我们将探讨 MSCs 作为载有抗癌药物的纳米颗粒（NPs）的靶向输送载体的潜力，总结各种挑战，并讨论这些挑战的可能解决方案。
在这篇综述中，讨论了基于间充质干细胞的抗癌药物靶向输送的可行性。
